Lipocine Inc. (LPCN)

Market Cap	14.96M -24.0%
Revenue (ttm)	1.98M -82.3%
Net Income	-9.63M
EPS	-1.77
Shares Out	7.30M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,397,255
Open	2.010
Previous Close	9.250
Day's Range	1.810 - 2.110
52-Week Range	1.810 - 12.370
Beta	1.09
Analysts	Strong Buy
Price Target	15.00 (+631.71%)
Earnings Date	May 7, 2026

About LPCN

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 14
• Stock Exchange: NASDAQ
• Ticker Symbol: LPCN
• Website: https://www.lipocine.com

Analyst Summary

According to one analyst, the rating for LPCN stock is "Strong Buy" and the 12-month stock price target is $15.0.

Price Target

$15.0

(631.71% upside)

Analyst Consensus: Strong Buy